Clinical Trial Update: Tanespimycin in Treating Patients With Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of Tanespimycin in patients with stage III-IV melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage III Melanoma | Phase 2 | Status: TERMINATED